BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28842748)

  • 1. PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma.
    Koh YW; Han JH; Yoon DH; Suh C; Huh J
    Ann Hematol; 2017 Nov; 96(11):1883-1890. PubMed ID: 28842748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.
    Koh YW; Jeon YK; Yoon DH; Suh C; Huh J
    Tumour Biol; 2016 Jun; 37(6):7507-14. PubMed ID: 26678894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
    Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
    Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of COX-2 expression and correlation with Bcl-2 and VEGF expression, microvessel density, and clinical variables in classical Hodgkin lymphoma.
    Koh YW; Park C; Yoon DH; Suh C; Huh J
    Am J Surg Pathol; 2013 Aug; 37(8):1242-51. PubMed ID: 23851330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
    Roemer MG; Advani RH; Ligon AH; Natkunam Y; Redd RA; Homer H; Connelly CF; Sun HH; Daadi SE; Freeman GJ; Armand P; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Rodig SJ; Shipp MA
    J Clin Oncol; 2016 Aug; 34(23):2690-7. PubMed ID: 27069084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus positivity is associated with angiogenesis in, and poorer survival of, patients receiving standard treatment for classical Hodgkin's lymphoma.
    Koh YW; Han JH; Yoon DH; Suh C; Huh J
    Hematol Oncol; 2018 Feb; 36(1):182-188. PubMed ID: 28744882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD163 expression was associated with angiogenesis and shortened survival in patients with uniformly treated classical Hodgkin lymphoma.
    Koh YW; Park CS; Yoon DH; Suh C; Huh J
    PLoS One; 2014; 9(1):e87066. PubMed ID: 24489836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble PD-L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma.
    Veldman J; Alsada ZND; van den Berg A; Plattel WJ; Diepstra A; Visser L
    Br J Haematol; 2021 May; 193(3):506-514. PubMed ID: 33620088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.
    Tanaka Y; Maeshima AM; Nomoto J; Makita S; Fukuhara S; Munakata W; Maruyama D; Tobinai K; Kobayashi Y
    Eur J Haematol; 2018 May; 100(5):511-517. PubMed ID: 29377256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocan-expressing microvessel density as a prognostic factor for survival in human gastric cancer.
    Chang Y; Niu W; Lian PL; Wang XQ; Meng ZX; Liu Y; Zhao R
    World J Gastroenterol; 2016 Jun; 22(23):5422-9. PubMed ID: 27340359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.
    Paydas S; Bağır E; Seydaoglu G; Ercolak V; Ergin M
    Ann Hematol; 2015 Sep; 94(9):1545-52. PubMed ID: 26004934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GLUT1 as a Prognostic Factor for Classical Hodgkin's Lymphoma: Correlation with PD-L1 and PD-L2 Expression.
    Koh YW; Han JH; Park SY; Yoon DH; Suh C; Huh J
    J Pathol Transl Med; 2017 Mar; 51(2):152-158. PubMed ID: 28219001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
    Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H
    Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma?
    Ek ET; Ojaimi J; Kitagawa Y; Choong PF
    Oncol Rep; 2006 Jul; 16(1):17-23. PubMed ID: 16786118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histological expression of angiogenic factors: VEGF, PDGFRalpha, and HIF-1alpha in Hodgkin lymphoma.
    Passam FH; Alexandrakis MG; Kafousi M; Fotinou M; Darivianaki K; Tsirakis G; Roussou PA; Stathopoulos EN; Siafakas NM
    Pathol Res Pract; 2009; 205(1):11-20. PubMed ID: 18950958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer.
    Zhou S; Wang GP; Liu C; Zhou M
    BMC Cancer; 2006 Sep; 6():231. PubMed ID: 17010208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis of invasive breast cancer after adjuvant therapy evaluated with VEGF microvessel density and microvascular imaging.
    Li Y; Wei X; Zhang S; Zhang J
    Tumour Biol; 2015 Nov; 36(11):8755-60. PubMed ID: 26052072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma.
    Abdulrauf SI; Edvardsen K; Ho KL; Yang XY; Rock JP; Rosenblum ML
    J Neurosurg; 1998 Mar; 88(3):513-20. PubMed ID: 9488306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
    Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
    BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
    Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Nuti M; Taube ET; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
    Br J Cancer; 2018 Aug; 119(3):330-338. PubMed ID: 29955134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.